NCT07649096

A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-10-29Est. Completion: 2028-08-22

Enrollment target: 56 participants

Locations

Alliance for Multispecialty Research, LLC - Knoxville, Knoxville, Tennessee, United States

Contact

William B Smithwilliam.smith@amr-clinical.com 18663059100

Other microbiome trials you might be interested in

Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile NeutropeniaPhase 4Completed

Neutropenia, Febrile

The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection i…

Leuven, BelgiumCompleted Mar 8, 2026

View Trial →

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID DiagnosticsPhase 4Recruiting

Blood Stream InfectionsVentilator Associated PneumoniaHealthcare Associated InfectionCarbapenem-Resistant Enterobacteriaceae InfectionHospital-acquired Pneumonia

RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority tr…

Vellore, India

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.